GlaxoSmithKline agreed to plead guilty to misdemeanor criminal charges and pay $3 billion to settle a healthcare fraud case involving the illegal promotion of the antidepressant Paxil to patients under 18, and Wellbutrin for unapproved indications, according to an investigation led by the U.S. Justice Department. The settlement also included charges that GSK failed to provide the FDA with safety data about its diabetes drug Avandia. The agreement, pending court approval, would resolve allegation...